Medical Oncology

Papers
(The TQCC of Medical Oncology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Oncotype DX testing does not affect clinical practice in stage IIa colon cancer57
The role of inflammatory indices in the outcome of COVID-19 cancer patients32
COVID-19 pandemic: a new cause of unplanned interruption of radiotherapy in breast cancer patients27
The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer22
How to ensure uninterrupted treatment of radiotherapy patients during delta variants of SARS-CoV-2 virus epidemic: the latest experience from Xi’an, China20
The inhibition of Panc1 cancer cells invasion by hAMSCs secretome through suppression of tyrosine phosphorylation of SGK223 (at Y411 site), c-Src (at Y416, Y530 sites), AKT activity, and JAK1/Stat3 si19
Innovation in cancer therapeutics and regulatory perspectives17
AFP peptide (AFPep) as a potential growth factor for prostate cancer15
Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model15
Mefenamic acid as a promising therapeutic medicine against colon cancer in tumor-bearing mice15
Interferon regulatory factor-1 regulates cisplatin-induced apoptosis and autophagy in A549 lung cancer cells14
A linkage between effectual genes in progression of CRC through canonical and non-canonical TGF-β signaling pathways14
AICAR enhances the cytotoxicity of PFKFB3 inhibitor in an AMPK signaling-independent manner in colorectal cancer cells13
DNA methylation marker to estimate ovarian cancer cell fraction13
In silico bioinformatics analysis for identification of differentially expressed genes and therapeutic drug molecules in Glucocorticoid-resistant Multiple myeloma13
Resveratrol triggers anti-proliferative and apoptotic effects in FLT3-ITD-positive acute myeloid leukemia cells via inhibiting ceramide catabolism enzymes12
Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells12
Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention12
Silencing Akt1 enhances the resistance of prostate cancer cells to starvation and inhibits starvation-induced lung metastasis through epithelial–mesenchymal transition in prostate cancer12
The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8+ T cells in bladder cancer12
0.050029039382935